TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03417830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698 (CPHPC)
Description: GSK2315698 will be administered as 20 milligrams per hour (20 mg/hour) IV infusion (in the vein) for up to 72 hours followed by 60 milligrams (mg) three times daily as SC injection for 8 days. Dose level and frequency will be adjusted according to renal function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698 (CPHPC)
Description: GSK2315698 will be administered as 20 milligrams per hour (20 mg/hour) IV infusion (in the vein) for up to 72 hours followed by 60 milligrams (mg) three times daily as SC injection for 8 days. Dose level and frequency will be adjusted according to renal function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2398852 (unlabeled anti-SAP mAb)
Description: Subjects will be administered up to 490 mg of GSK2398852, IV. Dose level will be adjusted based on emerging imaging data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2398852 (unlabeled anti-SAP mAb)
Description: Subjects will be administered up to 490 mg of GSK2398852, IV. Dose level will be adjusted based on emerging imaging data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)
Description: 89Zr-GSK2398852 will be available as solution containing 10 mg 89Zr-GSK2398852 for Infusion. Subjects will be administered 37 (Megabecquerel) MBq radioactive dose of 89Zr-GSK2398852 by the IV route at each dosing session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)
Description: 89Zr-GSK2398852 will be available as solution containing 10 mg 89Zr-GSK2398852 for Infusion. Subjects will be administered 37 (Megabecquerel) MBq radioactive dose of 89Zr-GSK2398852 by the IV route at each dosing session.
Study: NCT02246088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MT + NE
Description: Manual therapy will be applied using mobilization with movement (MWM) techniques. MWM will consist of a sustained manual glide of the tibia (either medial, lateral, anterior, posterior, or rotation) during active knee flexion and extension, depending on which are the limited/painful movements for each patient.~The content and pictures of the neuroscience education (NE) will be based on the text Explicando el dolor (Spanish version of Explain Pain).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MT + E
Description: Program of education based on the traditional biomedical model (i.e. through visualization of several videos related to anatomy, biomechanics and surgical procedure of the knee), plus the same manual treatment as per the MT+NE group
Study: NCT04051216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education information system
Description: Participants will receive a mobile tablet as an educational intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity monitor
Description: Participants will receive at least 1 of 4 activity monitoring devices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participants will be interviewed about their experience using the device(s)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Participants will receive surveys

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03449199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMX-049
Description: A certain dose of TMX-049 to be taken orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMX-049
Description: A certain dose of TMX-049 to be taken orally, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to be taken orally, once daily
Study: NCT00805402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: flow cytometry
Study: NCT00890331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeamWork CS Sessions
Description: The intervention focuses on an authoritative parenting approach that emphasizes continued parental involvement in daily disease care. Dyadic coping skills of communication, problem solving, conflict resolution, along with attitude and behavior change are highlighted. Families meet with a study interventionist in conjunction with four consecutive medical appointments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education
Description: Diabetes Education The education comparison group meets with an educational interventionist in conjunction with four consecutive medical appointments. This group focuses on diabetes educational and resource support for parents and their youth with type 1 diabetes.
Study: NCT04341272

Intervention type: DEVICE
Group type: OTHER
Intervention: Intermittent Pneumatic Compression Device (FDA approved)
Description: Compression Device placed on either upper or lower extremity for DVT prophylaxis following surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Pneumatic Compression Device (FDA approved)
Description: Compression Device placed on either upper or lower extremity for DVT prophylaxis following surgery
Study: NCT03188692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPT-IPV-Hib (Combined Vaccine)
Description: 0.5mL, intramuscular injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
Study: NCT04100824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stellate ganglion block by transcranial doppler
Description: stellate ganglion block is a block of sympathetic ganglion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine
Description: Nimodipine 60mg every 4h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine
Description: Nimodipine 60mg every 4h
Study: NCT00798382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soy protein formula
Description: ad lib for 0-35 days of age

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available soy formula
Description: ad lib for 0-35 days of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy formula experimental #2
Description: ad lib for 0-35 days of age
Study: NCT00611884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Treat-to-target dose titration scheme, s.c. injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Formulation D: Treat-to-target dose titration scheme, s.c. injection, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Formulation E: Treat-to-target dose titration scheme, s.c. injection, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Formulation D: Treat-to-target dose titration scheme, s.c. injection, 3 times weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 1500-2000 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 1500-2000 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 1500-2000 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 1500-2000 mg/day
Study: NCT01046578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 12 mm in diameter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 18 mm in diameter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 20 mg, one tablet a day for one day, starting 24-48 hours after ovulation of the dominant follicle is observed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg, one tablet a day for five days, starting 24-48 hours after ovulation of the dominant follicle is observed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
Study: NCT04531787

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season: 2004-2005, 2005-2006, 2006-2007, 2007-2008 for season specific A/H1N1, A/H3N2, and B antigens

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season: 2004-2005, 2005-2006, 2006-2007, 2007-2008 for season specific A/H1N1, A/H3N2, and B antigens

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season: 2004-2005, 2005-2006, 2006-2007, 2007-2008 for season specific A/H1N1, A/H3N2, and B antigens
Study: NCT02910414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydrated alcohol
Description: Dehydrated Alcohol Injection, USP is used in the study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Peregrine System Kit (Sham Procedure)
Description: Pre-procedural diagnostic renal angiography only, performed for confirmation of anatomical eligibility prior to randomization
Study: NCT04191824

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: APOL1 status
Description: Participants will be randomized to immediate versus delayed return of results for positive or negative APOL1 status.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: APOL1 status
Description: Participants will be randomized to immediate versus delayed return of results for positive or negative APOL1 status.
Study: NCT01301924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: Meglumine antimoniate is stored and ministered under actual conditions employed by health services in Brazil. Each patient will be included in one of the treatment groups with meglumine antimoniate IM:~High dose: 20 days of 20 mg/kg/day antimoniate meglumine. Low dose: 30 days of 5 mg/kg/day antimoniate meglumine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate
Description: Meglumine antimoniate is stored and ministered under actual conditions employed by health services in Brazil. Each patient will be included in one of the treatment groups with meglumine antimoniate IM:~High dose: 20 days of 20 mg/kg/day antimoniate meglumine. Low dose: 30 days of 5 mg/kg/day antimoniate meglumine.
Study: NCT02443324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV
Study: NCT05006495

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: C3 laminectomy
Description: C3 laminectomy preserving semispinalis cervicis inserted into the axis.
Study: NCT02889341

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Study: NCT05006495

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: C3 laminoplasty
Description: Conventional C3-6 laminoplasty, resulting in injury of semispinalis cervicis.
Study: NCT02889341

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02443324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV
Study: NCT02646917

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aesthetic Microneedling Treatment
Description: Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.
Study: NCT01656681

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: THIAA
Description: A tablet containing 400 mg tetrahydro iso-alpha acids, 3 times a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT03568799

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-(2S,4R)4-fluoroglutamine
Description: Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
Study: NCT01709266

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00347555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum Phosphate
Description: 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum Phosphate
Description: 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum Phosphate
Description: 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.
Study: NCT01652976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 150mg PO daily on days 1-14 of each 14 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle
Study: NCT03030326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: heart rate variability biofeedback
Description: Patients learn to increase heart rate variability by breathing at the resonance frequency of the cardiovascular system, at approximately 6 breaths/min, varying among people.
Study: NCT01611207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith \& Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Wound Therapy
Description: Standard wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
Study: NCT00444821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AneuRx AAA stent graft / Talent AAA stent graft
Description: Catheter based stent graft inserted to seal off an abdominal aortic aneurysm
Study: NCT02483338

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment of pain
Description: Assessment of pain using FASS but without using this score to manage pain
Study: NCT01562626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APS001F
Description: APS001F infusion on Days 1,2,3 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucytosine (5-FC)
Description: oral doses on Days 11-15 and 18-22, each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% maltose
Description: 10% maltose infusion will be administered on Days 1-5, 8-12, and 15-19, each 28 day cycle.
Study: NCT03550534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Calcium carbonate was obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule was also obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
Study: NCT00206102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine fumarate
Description: flexible dose oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: flexible dose oral
Study: NCT00906373

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)
Description: intravenous infusions 10 mg/kg on Day 1 of each 3-week cycle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMC-A12 (cixutumumab) - 20 mg/kg
Description: intravenous infusions 20 mg/kg on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 milligrams (mg) twice per day orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 milligrams (mg) twice per day orally
Study: NCT01645917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Front Advance Cardiac CryoAblation system
Description: Standard of care ablation for indicated paroxysmal AF patients with Medtronic's Arctic Front Advance Cardiac CryoAblation system
Study: NCT03434769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60mg/Kg on day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m\^2 IV on days -5 to -3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T Cells
Description: Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0~Level -1 (1 x 105 cells/kg)~Level 1 \[Starting dose\] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)
Study: NCT04171440

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic pancreaticoduodenectomy
Description: The robotic pancreaticoduodenectomy is performed through small incisions using robotic-assisted technology. Pancreaticoduodenectomy is the operation that is necessary to remove tumors of the head and neck of the pancreas, lower portion of the bile duct, and the ampulla of Vater.
Study: NCT03990480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan (160 mg/d)
Description: Group I treated with valsartan (160 mg/d, n = 100)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine (10 mg/d).
Description: Group II amlodipine (10 mg/d, n = 100).
Study: NCT02377180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramuscular capsaicin injection
Description: Intramuscular injection of capsaicin: 50 mcg/0.5 ml

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprascapular nerve block
Description: Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus or trapezius muscle in randomized order, followed by suprascapular nerve block (ultrasound-guided) using Lidocaine 1%; nerve block is expected to be effective only in pain arising from the supraspinatus muscle. Trapezius pain serves as control condition.~Evaluates the diagnostic validity of suprascapular nerve block for muscle pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic infiltration
Description: Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus muscle in two different sessions; suprascapular nerve block in one session and intramuscular local anesthetic infiltration in one session (in randomized order) using Lidocaine 1%; the aim is to investigate which procedure provides faster and more efficient pain relief. Compares effectivity of suprascapular nerve block vs. intramuscular local anesthetic infiltration.
Study: NCT01810250

Intervention type: DEVICE
Intervention: Endurant Stent Graft
Study: NCT02251613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine HCl ophthalmic solution, 0.1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinastine HCl ophthalmic solution, 0.05%
Study: NCT02696707

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LVEF 3 month
Description: cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LVEF 4 month
Description: cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
Study: NCT02940561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate - Amneal
Description: Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate, USP and are round, biconvex, yellow tablets, scored in half on one side, engraved with A above the score and 1 below
Study: NCT02503722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02940561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate - DAVA
Description: Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, yellow tablets, scored in half on one side, engraved with M above the score, and 1 below
Study: NCT02503722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study: NCT01173744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma-3 Nail
Description: Gamma-3 Nail (stryker)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DHS
Description: DHS (Zimmer)